Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.

They want to gain a deeper understanding of why the disease behaves differently in these patients. Read more at ...

Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...

With ever-growing treatment options, clinical care access and a new focus on integrative strategies, cancer centers are constantly upgrading their services and options for patients. Becker’s asked ...

This week’s edition of The Targeted Pulse spotlights 5 key developments shaping the landscape of targeted oncology.

Lung cancer may be curable, depending on a number of factors, including your age, health, stage of cancer, and how it ...

Recent developments in protein-protein interactions (PPI) give hope for patients with advanced or untreatable diseases.

The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.

Eight years after it was established partly by AstraZeneca, Dizal Pharmaceuticals has gained its first FDA approval, winning an accelerated nod for Zegfrovy (sunvozertinib) to become the only ...